Vaughn DJ - Search Results

1

Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, Chen I, Schwartz G. Vaughn DJ, et al. N Engl J Med. 2009 Jan 22;360(4):423-4. doi: 10.1056/NEJMc0808558. N Engl J Med. 2009. PMID: 19164198 Clinical Trial. No abstract available.

2

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.

Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ. Vaughn DJ, et al. Cancer. 2015 May 1;121(9):1463-8. doi: 10.1002/cncr.29213. Epub 2014 Dec 18. Cancer. 2015. PMID: 25522918 Free article. Clinical Trial.

3

Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.

Narayan V, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ, Vaughn DJ. Narayan V, et al. Among authors: vaughn dj. Clin Genitourin Cancer. 2016 Dec;14(6):504-510. doi: 10.1016/j.clgc.2016.03.010. Epub 2016 Mar 12. Clin Genitourin Cancer. 2016. PMID: 27055371 Clinical Trial.

4

Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ. Clark AS, et al. Among authors: vaughn dj. JAMA Oncol. 2016 Feb;2(2):253-60. doi: 10.1001/jamaoncol.2015.4701. JAMA Oncol. 2016. PMID: 26633733 Review.

5

Early treatment-related neutropenia predicts response to palbociclib.

McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A. McAndrew NP, et al. Br J Cancer. 2020 Sep;123(6):912-918. doi: 10.1038/s41416-020-0967-7. Epub 2020 Jul 9. Br J Cancer. 2020. PMID: 32641862 Free PMC article.

6

Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer.

Flaherty KT, Malkowicz SB, Vaughn DJ. Flaherty KT, et al. Among authors: vaughn dj. Am J Clin Oncol. 2004 Apr;27(2):136-9. doi: 10.1097/01.coc.0000054888.02055.4e. Am J Clin Oncol. 2004. PMID: 15057152 Clinical Trial.

7

Phase I trial of combretastatin a-4 phosphate with carboplatin.

Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. Bilenker JH, et al. Clin Cancer Res. 2005 Feb 15;11(4):1527-33. doi: 10.1158/1078-0432.CCR-04-1434. Clin Cancer Res. 2005. PMID: 15746056 Clinical Trial.

8

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.

Bilenker JH, Stevenson JP, Gallagher ML, Vaughn D, Cohen MB, O'Dwyer PJ. Bilenker JH, et al. Br J Cancer. 2004 Jul 19;91(2):213-8. doi: 10.1038/sj.bjc.6601885. Br J Cancer. 2004. PMID: 15213727 Free PMC article. Clinical Trial.

9

Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.

Sun W, Stevenson JP, Gallagher ML, Vaughn D, Hahn SM, Haller DG, Cohen M, Kopit J, Gallant G, O'Dwyer PJ. Sun W, et al. Clin Cancer Res. 2003 Nov 1;9(14):5221-7. Clin Cancer Res. 2003. PMID: 14614002 Clinical Trial.

10

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.

Sun W, Stevenson JP, Gallagher M, Giantonio B, Algazy K, Haller D, Vaughn D, Raskay BJ, O'Dwyer PJ. Sun W, et al. Cancer. 2001 Jul 15;92(2):414-9. doi: 10.1002/1097-0142(20010715)92:2<414::aid-cncr1337>3.0.co;2-w. Cancer. 2001. PMID: 11466697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page